In the ENVISION study, UGN-102 demonstrated a 79.6% three-month complete response rate and 82.3% duration of response at 12 months — reinforcing the company's lead candidate's potential to be the first FDA-approved nonsurgical option for treatment of low-grade intermediate-risk NMIBC.
UGN-102, delivered to patients using a urinary catheter in an outpatient setting, is designed to enable longer exposure of bladder tissue to mitomycin, thereby enabling the treatment of tumors by nonsurgical means. The treatment utilizes UroGen’s proprietary RTGel technology, a sustained release, hydrogel-based formulation.
Low-grade intermediate-risk NMIBC's highly recurrent nature often means patients must undergo numerous surgeries throughout their lifetime, so UGN-102, if approved, could provide a minimally invasive option.
In January 2024, UroGen initiated the submission of a rolling NDA to the FDA for UGN-102 and this latest data will support that application. UroGen says a potential FDA decision could come as early as the first quarter of 2025.